553 related articles for article (PubMed ID: 11965605)
21. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma.
Kwekkeboom DJ; Bakker WH; Kooij PP; Erion J; Srinivasan A; de Jong M; Reubi JC; Krenning EP
Eur J Nucl Med; 2000 Sep; 27(9):1312-7. PubMed ID: 11007512
[TBL] [Abstract][Full Text] [Related]
22. Radiolabeling approaches for cholecystokinin B receptor imaging.
Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
[TBL] [Abstract][Full Text] [Related]
23. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
[TBL] [Abstract][Full Text] [Related]
24. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors.
Roosenburg S; Laverman P; van Delft FL; Boerman OC
Amino Acids; 2011 Nov; 41(5):1049-58. PubMed ID: 20198494
[TBL] [Abstract][Full Text] [Related]
25. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
26. Expression of cholecystokinin-B/gastrin receptors in medullary thyroid cancer.
Amiri-Mosavi A; Ahlman H; Tisell LE; Wängberg B; Kölby L; Forssell-Aronsson E; Lundberg PA; Lindstedt G; Nilsson O
Eur J Surg; 1999 Jul; 165(7):628-31. PubMed ID: 10452255
[TBL] [Abstract][Full Text] [Related]
27. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Fröberg AC; de Jong M; Nock BA; Breeman WA; Erion JL; Maina T; Verdijsseldonck M; de Herder WW; van der Lugt A; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
[TBL] [Abstract][Full Text] [Related]
28. Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.
Klingler M; Hörmann AA; Guggenberg EV
Curr Med Chem; 2020; 27(41):7112-7132. PubMed ID: 32586246
[TBL] [Abstract][Full Text] [Related]
29. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
[TBL] [Abstract][Full Text] [Related]
30. Intraoperative gamma probe detection of neuroendocrine tumors.
Adams S; Baum RP; Hertel A; Wenisch HJ; Staib-Sebler E; Herrmann G; Encke A; Hör G
J Nucl Med; 1998 Jul; 39(7):1155-60. PubMed ID: 9669386
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
32. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
33. Functional nuclear medicine imaging of medullary thyroid cancer.
Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D
Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370
[TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.
von Guggenberg E; Rangger C; Sosabowski J; Laverman P; Reubi JC; Virgolini IJ; Decristoforo C
Mol Imaging Biol; 2012 Jun; 14(3):366-75. PubMed ID: 21732165
[TBL] [Abstract][Full Text] [Related]
35. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
[TBL] [Abstract][Full Text] [Related]
36. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
37. High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents.
Schaer JC; Reubi JC
J Clin Endocrinol Metab; 1999 Jan; 84(1):233-9. PubMed ID: 9920090
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
